Targeted Therapy for Metastatic Cancer
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 305
Special Issue Editor
Interests: oral cancer; oral submucous fibrosis; metastasis; targeted therapy; cell signaling; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is one of the leading causes of death worldwide. Therapeutic interventions for primary and metastatic cancers are surgery with chemotherapy and/or radiation. Our understanding of tumor genetics, transcriptome, and proteome coupled with knowledge of the evolving genetic landscape of metastatic tumor has paved the way for precision medicine. Targeted therapies exploit the dependency of tumor cells on key cellular proteins that drive tumor proliferation and metastasis. These therapies primarily comprise biologics such as immunotherapy, monoclonal antibodies, or small molecule inhibitors. Recent advances have also focused on cell-based and gene therapies. New methodologies of drug delivery systems and drug activation by triggers such as light are also promising therapeutics.
This Special Issue will highlight the current advancements and challenges in targeted therapies for cancer. It will provide insights into the discovery of cellular targets for targeted therapy; advancements in methodologies for the delivery of targeted therapy; and focus on resistance mechanisms as well.
Dr. Ila Pant
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- monoclonal antibodies
- DNA- or RNA-based targeted therapy
- small molecule inhibitors
- targeted nano-delivery systems
- resistance to targeted therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
